|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0183683,
umls-concept:C0205156,
umls-concept:C0344211,
umls-concept:C0439859,
umls-concept:C0442967,
umls-concept:C1171411,
umls-concept:C1317973,
umls-concept:C1328050,
umls-concept:C1521721,
umls-concept:C2323499
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1999-10-25
|
|
pubmed:abstractText |
Twenty-six patients with breast cancer who had relapsed after previously receiving high-dose chemotherapy and autologous hematopoietic cell support received a second course of high-dose cytoreductive therapy and autologous hematopoietic cell support as salvage therapy. Several different high-dose therapy regimens were employed for the second transplant, including a radiolabeled immunoconjugate. Two patients died of treatment-related complications. The remaining 24 patients relapsed a median of 126 (range 22-635) days after salvage transplant. All have since died. The median survival after salvage transplant was 362 (range 31-931) days. We conclude that second courses of high-dose therapy as salvage treatment are generally well-tolerated but their efficacy is modest. Alternative treatment strategies are needed for these patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
491-5
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10482932-Adult,
pubmed-meshheading:10482932-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10482932-Breast Neoplasms,
pubmed-meshheading:10482932-Carboplatin,
pubmed-meshheading:10482932-Carmustine,
pubmed-meshheading:10482932-Cisplatin,
pubmed-meshheading:10482932-Combined Modality Therapy,
pubmed-meshheading:10482932-Cyclophosphamide,
pubmed-meshheading:10482932-Disease-Free Survival,
pubmed-meshheading:10482932-Female,
pubmed-meshheading:10482932-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10482932-Humans,
pubmed-meshheading:10482932-Ifosfamide,
pubmed-meshheading:10482932-Life Tables,
pubmed-meshheading:10482932-Melphalan,
pubmed-meshheading:10482932-Middle Aged,
pubmed-meshheading:10482932-Neoplasm Metastasis,
pubmed-meshheading:10482932-Paclitaxel,
pubmed-meshheading:10482932-Salvage Therapy,
pubmed-meshheading:10482932-Survival Analysis,
pubmed-meshheading:10482932-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
|
|
pubmed:affiliation |
Bone Marrow Transplant Programs, University of Colorado Health Sciences Center, Denver, CO, USA.
|
|
pubmed:publicationType |
Journal Article
|
